Get the Stockscreener App
15.05
0.13%
0.02
After Hours:
15.05
Anika Therapeutics Inc stock is traded at $15.05, with a volume of 113.35K.
It is up +0.13% in the last 24 hours and down -13.75% over the past month.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
See More
Previous Close:
$15.03
Open:
$15.13
24h Volume:
113.35K
Relative Volume:
1.63
Market Cap:
$213.35M
Revenue:
$166.88M
Net Income/Loss:
$-74.18M
P/E Ratio:
-2.9684
EPS:
-5.07
Net Cash Flow:
$1.14M
1W Performance:
-0.73%
1M Performance:
-13.75%
6M Performance:
-39.85%
1Y Performance:
-41.73%
1-Day Range:
$14.77
$15.45
1-Week Range:
$14.77
$15.79
52-Week Range:
$14.77
$29.11
Anika Therapeutics Inc Stock (ANIK) Company Profile
Name
Anika Therapeutics Inc
Sector
Phone
(781) 457-9000
Address
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
15.05 | 213.35M | 166.88M | -74.18M | 1.14M | -5.07 |
|
ZTS
Zoetis Inc
|
163.50 | 72.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.98 | 47.08B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.16 | 45.99B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.29 | 17.52B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
312.26 | 13.78B | 2.76B | 1.11B | 898.10M | 22.77 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-24 | Reiterated | Barrington Research | Outperform |
| Aug-14-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Mar-07-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-09-22 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-14-22 | Resumed | Stephens | Equal-Weight |
| Mar-09-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-09-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-16-21 | Initiated | Stephens | Overweight |
| Jul-16-21 | Initiated | UBS | Neutral |
| Dec-16-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-21-20 | Upgrade | Sidoti | Neutral → Buy |
| Jan-10-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Nov-05-19 | Initiated | BWS Financial | Sell |
| Sep-24-19 | Reiterated | Barrington Research | Outperform |
| Sep-23-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Strong Buy |
| Feb-22-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Feb-22-19 | Downgrade | Sidoti | Buy → Neutral |
| Jul-27-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jun-20-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-20-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| May-04-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Feb-23-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-24-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Oct-27-17 | Reiterated | Barrington Research | Outperform |
| May-09-16 | Upgrade | Singular Research | BUY - Long-Term → Buy |
| Apr-27-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-26-16 | Reiterated | Barrington Research | Outperform |
View All
Anika Therapeutics Inc Stock (ANIK) Latest News
Viscosupplementation Market Is Booming Worldwide | Anika - openPR.com
Europe Viscosupplementation Market Projected To Witness - openPR.com
Anika Therapeutics stock hits 52-week low at $14.9 By Investing.com - Investing.com South Africa
Anika Therapeutics stock hits 52-week low at $14.9 - Investing.com India
How the (ANIK) price action is used to our Advantage - news.stocktradersdaily.com
Anika Therapeutics, Inc. (NASDAQ:ANIK) Stock Position Reduced by Charles Schwab Investment Management Inc. - Defense World
Hammertoe Solution Market Size, Trends 2031 By Key Players- - openPR.com
Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Acquired by Bank of New York Mellon Corp - Defense World
Europe Viscosupplementation Market Set to Witness Significant - openPR.com
Reviewing Anika Therapeutics (NASDAQ:ANIK) and InspireMD (NYSE:NSPR) - Defense World
Anika Therapeutics Faces Financial Strain Amid Geopolitical Tensions and Supply Chain Disruptions - TipRanks
Anika Therapeutics, Inc. SEC 10-K Report - TradingView
Viscosupplementation Market Is Booming Worldwide | Anika Therapeutics Inc., Seikagaku Corporation - openPR.com
Q1 Earnings Forecast for ANIK Issued By Barrington Research - Defense World
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2024 Earnings Call Transcript - MSN
Anika Therapeutics (NASDAQ:ANIK) Stock Rating Upgraded by StockNews.com - Defense World
Barrington Research Lowers Anika Therapeutics (NASDAQ:ANIK) Price Target to $20.00 - Defense World
Anika Therapeutics (NASDAQ:ANIK investor three-year losses grow to 45% as the stock sheds US$26m this past week - Simply Wall St
Anika Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Anika Therapeutics stock hits 52-week low at $15.34 By Investing.com - Investing.com Australia
Anika Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Anika Therapeutics stock hits 52-week low at $15.34 - Investing.com
Earnings call transcript: Anika Therapeutics Q4 2024 beats EPS forecast, stock dips - Investing.com Australia
Anika Therapeutics Inc (ANIK) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges - Yahoo Finance
Anika Therapeutics Reports Steady Growth and Strategic Focus - TipRanks
Earnings call transcript: Anika Therapeutics Q4 2024 beats EPS forecast, stock dips By Investing.com - Investing.com South Africa
Anika Therapeutics (ANIK) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Anika Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Anika: Q4 Earnings Snapshot -March 12, 2025 at 04:34 pm EDT - Marketscreener.com
ANIKA THERAPEUTICS Earnings Results: $ANIK Reports Quarterly Earnings - Nasdaq
Anika Therapeutics Q4 Swings to Adjusted Loss, Revenue Rises -- Shares Drop After Hours - Marketscreener.com
Anika Therapeutics, Inc. Reports 2024 Financial Results with 17% Growth in Commercial Channel Revenue and Key Strategic Advances - Nasdaq
Anika Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Anika's Commercial Channel Soars 25% in Q4: Inside the Transformation Strategy - StockTitan
Anika: Q4 Earnings Snapshot - CT Insider
Anika Therapeutics Sells Parcus Medical to Medacta - TipRanks
Anika Therapeutics at CG 2025 Musculoskeletal Conference: Strategic Growth Unveiled - Investing.com Canada
Anika Therapeutics at CG 2025 Musculoskeletal Conference: Strategic Growth Unveiled By Investing.com - Investing.com South Africa
ANIKA THERAPEUTICS Earnings Preview: Recent $ANIK Insider Trading, Hedge Fund Activity, and More - Nasdaq
Anika Therapeutics Reports Third-Quarter Financial Results - AOL
(ANIK) Investment Report - news.stocktradersdaily.com
Anika Therapeutics falls after its completes divestiture of Parcus Medical business - TradingView
Anika Completes Divestiture of Parcus Medical - citybiz
Anika Therapeutics Completes Divestiture of Parcus Medical to Medacta -March 07, 2025 at 06:38 am EST - Marketscreener.com
Anika Therapeutics (ANIK) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Anika Therapeutics Completes Sale of Parcus Medical to Medacta Group SA - Nasdaq
Can Anika's Strategic Exit from Parcus Medical Transform Its Growth Trajectory? - StockTitan
Knee Cartilage Repair Market Generated Opportunities, Future - openPR
Anika Therapeutics (ANIK) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Anika Therapeutics Inc Stock (ANIK) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.06%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):